comparemela.com

Latest Breaking News On - Leukocyte interleukin - Page 18 : comparemela.com

CEL-SCI Increases Previously Announced Bought Deal to $31 7 Million

VIENNA, Va. (BUSINESS WIRE) $CVM CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that, due to demand, the underwriter has agreed to increase the size of its previously announced offering and purchase on a firm commitment basis 1,400,000 shares of common stock of t.

CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference

CEL-SCI Corporation to Present at the 13th Annual LD Micro Main Event Conference CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 13 th Annual LD Micro Main Event Conference on Tuesday, December 15, 2020 at 10:00 a.m. ET. Geert Kersten, Chief Executive Officer of CEL-SCI, will be presenting to a live virtual audience. CEL-SCIs presentation will be broadcast live at https://ve.mysequire.com/company?company id=7413c04b-9bf8-491b-9f2a-88228de5695a or on the Investor Relations section of CEL-SCIs website at cel-sci.com/new-investor-information/. LD Micros Main Event will feature a new format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.